Abstract
The pharmacokinetic properties of fluconazole were studied in more than 100 pediatric patients, including 12 premature neonates. The volume of distribution and the rate of elimination differed significantly from the values reported for adults. The volume of distribution varied with age, being greatest during the neonatal period (1.18 to 2.25 l/kg) and decreasing by young adulthood to a value similar to that reported for adults (0.7 l/kg). With the exception of neonates, fluconazole clearance was generally more rapid in children than in adults, with a mean plasma elimination half-life of just over 20 h for all pediatric age groups. In neonates, fluconazole was eliminated slowly, with a mean elimination half-life of 88.6 h at birth, 67.5 h approximately one week later and 55.2 approximately two weeks after birth. Fluconazole appeared to be well absorbed from the gastrointestinal tract. These pharmacokinetic results, taken in conjunction with the corresponding data for adults, provide a sound basis for establishing appropriate fluconazole dosage recommendations for pediatric patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Viscoli C, Castagnola E, Fioredda F, Ciravegna B, Barigione G, Terragna A Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrobial Agents and Chemotherapy 1991, 35: 365–367.
Bode S, Pedersen-Bjergaard L, Hjelt K Candida albicans septicemia in a premature infant successfully treated with oral fluconazole. Scandinavian Journal of Infectious Diseases 1992, 24: 673–675.
Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. Journal of Pediatrics 1992, 120: 987–993.
Saxen H, Hoppu K, Pohjavuori M Pharmacokinetics of fluconazole in very low birthweight infants during the first two weeks of life. Clinical Pharmacology and Therapeutics 1993, 54: 269–277.
Macrae PV Quantitative analysis of the antifungal agent fluconazole by capillary gas chromatography with ion trap detection. In: Reid E (ed): Methodological surveys in biochemistry and analysis. Royal Society of Chemistry, London, 1990, p. 145–152.
Wallace JE, Harris SC, Gallegos J, Foulds G, Chen TJH, Rinaldi MG Assay of fluconazole by high performance liquid chromatography with a mixed-phase column. Antimicrobial Agents and Chemotherapy 1992, 36: 603–606.
Harris SC, Wallace JE, Foulds G, Rinaldi MG Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrobial Agents and Chemotherapy 1989, 33: 714–716.
Milsap RL, Szefler SJ Special pharmacokinetic considerations in children. In: Evans WE, Schentag JJ, Jusko WJ (ed): Applied pharmacokinetics. Applied Therapeutics Publishing, Spokane, WA, 1986, p. 294–330.
Brammer KW, Farrow PR, Faulkner JK Pharmacokinetics and tissuepenetration of fluconazole in humans.Reviews of Infectious Diseases 1990, 12, Supplement 3: 318–326.
Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH The disposition and metabolism of [14C] fluconazole in humans. Drug Metabolism and Disposition 1991, 19: 764–767.
Grant SM, Clissold SP Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990, 39: 877–916.
Paap CM, Nahat MC Clinical pharmacokinetics of antibacterial drugs. Clinical Pharmacokinetics 1990, 19: 280–318.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brammer, K.W., Coates, P.E. Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 13, 325–329 (1994). https://doi.org/10.1007/BF01974613
Issue Date:
DOI: https://doi.org/10.1007/BF01974613